A peritoneal dialysis (pd) patient on continuous cyclic pd (ccpd) therapy utilizing the liberty select cycler reported experiencing peritonitis.There was no specific allegation this adverse event was related to a deficiency or malfunction of any fresenius product(s) or device(s) in the initial reporting.Upon follow up with the patient¿s pd registered nurse, it was reported this patient was hospitalized on (b)(6) 2024 following abdominal pain.Peritoneal effluent fluid cultures and a white blood cell (wbc) count taken in the hospital on (b)(6) 2024 presented with no growth in the culture and an elevated wbc count (exact count not reported).The patient was diagnosed with peritonitis due to unknown etiology.The patient was prescribed intraperitoneal (ip) vancomycin at 2000 mg and ip ceftazidime at 2000 mg (frequency and duration not reported) to address the infection.The patient¿s pd catheter (not a fresenius product) was removed on (b)(6) 2024 during this hospitalization due to the severity of infection.The patient was transitioned to hemodialysis (hd) for renal replacement therapy through an existing arteriovenous access on a hospital provided hd machine (unknown brand and model) for the duration of the admission.The patient had an uneventful hospital course and was discharged to home on (b)(6) 2024.It was confirmed, though the exact source of infection remains unknown, there was no indication the patient¿s peritonitis, and the associated hospitalization were due to a deficiency or malfunction of any fresenius product(s) or device(s).The patient recovered from this event as remains asymptomatic on antibiotic therapy.The patient continues hd therapy on an in-center basis with a plan to return to pd therapy on the same liberty select cycler once cleared by his physician.
|